Giant cell tumor of bone is a benign albeit aggressive tumor commonly affecting the bones of
the knee. Patients with these tumors present with pain, swelling, and inability to bear weight …

Monocyte lineage cells play important roles in health and disease. Their differentiation into
macrophages is crucial for a broad array of immunologic processes that regulate …

Background Giant-cell tumour of bone (GCTB) is a rare, locally aggressive osteoclastogenic
stromal tumour of the bone. This phase 2 study aimed to assess the safety and activity of …

Denosumab is a monoclonal antibody against RANK ligand for treatment of giant cell tumor
of bone (GCTB). Clinical trials and case series have demonstrated that denosumab is …

Abstract Purpose of Review To highlight the new developments in the management of
advanced giant cell tumor of bone, a rare locally aggressive benign tumor, which was …

Nonmalignant bone tumors represent a wide variety of different entities but maintain many
common features. They usually affect young patients, and most can be diagnosed through …

Giant cell tumors of bone (GCTBs) are characterized by mononuclear stromal cells and
osteoclast-like giant cells; up to 95% have H3F3A gene mutation. The RANKL inhibitor …

Giant cell tumour of bone (GCTB) is a benign osteolytic tumour with three main cellular
components: multinucleated osteoclast-like giant cells, mononuclear spindle-like stromal …

Background Multinucleated giant cells have been noticed in diverse arthritic conditions
since their first description in rheumatoid synovium. However, their role in the pathogenesis …

Background The RANK ligand inhibitor denosumab is being investigated for treatment of
giant cell tumor of bone, but the available data in the literature remains sparse and …